Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.170
-0.085 (-3.77%)
At close: Feb 21, 2025, 4:00 PM
2.169
-0.001 (-0.04%)
After-hours: Feb 21, 2025, 7:45 PM EST
Allogene Therapeutics Employees
As of December 31, 2023, Allogene Therapeutics had 233 total employees, including 232 full-time and 1 part-time employees. The number of employees decreased by 128 or -35.46% compared to the previous year.
Employees
233
Change (1Y)
-128
Growth (1Y)
-35.46%
Revenue / Employee
$185
Profits / Employee
-$1,216,433
Market Cap
454.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ALLO News
- 9 days ago - Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology - GlobeNewsWire
- 25 days ago - Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - GlobeNewsWire
- 2 months ago - Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - GlobeNewsWire
- 3 months ago - Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire